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Abstract
Aim. Ethnic background and geographical location are important when measuring the incidence of gallbladder carcinoma
leading to variable mortality rates across the world. Method. Age standardized mortality rates [ASR(W)] were extracted
separately for males and females from a database maintained by the International Agency for Research on Cancer for 50
countries across the world (Europe 32; the Americas 8; and Asia 10) for the period 19922002 and log-linear regression was
performed to analyse trends in the last decade. Result. In the period 19922002, declining trends in mortality for both sexes
were observed in Germany, Sweden, Japan, USA, and Hungary (pB0.001), and in France, Canada, United Kingdom, The
Netherlands, and Hong Kong (pB0.01). Austria, Czechoslovakia, Slovenia, Denmark, Spain, and Israel exhibited decreasing
mortality trends more significant in women (pB0.01) than in men (pB0.05). Decreasing female mortality trends were seen in
Finland, Italy, and Portugal (pB0.01) and in Georgia, Luxembourg, and Belgium (pB0.05). Iceland, Costa Rica, and Korea
were the only countries with an increase in male mortality (pB0.05). Conclusions. Overall, there was a decline in ASR(W) for
gallbladder cancer. Better diagnostic modalities resulting in appropriate staging of gallbladder/biliary cancers, as well as
changes in the ICD classification and perhaps increased awareness, may have contributed to these trends.
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Introduction
Primary carcinoma of the gallbladder is the most
common biliary tract tumor and the sixth most
common cancer affecting the gastrointestinal tract
[1,2]. The majority of cases are diagnosed in the
advanced stages, leading to extremely poor prognosis.
The prognosis is mainly dependent on histological
subtype, grade, and stage of the tumor at the time of
presentation. The overall mean survival rate for
patients with gallbladder cancer (GBC) is 6 months,
with a 5-year survival rate of 5% [1].
GBC has a female predilection, especially women
65 years of age [3]. The commonest association of
GBC is with gallstones, i.e. larger stones contributing
to increased risk [4,5]. The other risk factors for
developing GBC include chronic infection of the
biliary tract, in particular due to Salmonella typhi,
chemical exposure, cigarette smoking, high parity,
post-menopausal state, diet, and obesity [3,68].
A unique feature of GBC is that it exhibits marked
geographic and ethnic variation [611]. We evaluated
the possible changes in mortality trends in GBC in
view of the relatively standardized diagnostic modal-
ities over the last 10 years (19922002).
Methods
The database maintained by the International Agency
for Research on Cancer (IARC)  the CANCER
Mondial Statistical Information System (http://
www.dep.iarc.fr/) was accessed and age standardized
mortality rate (world) [ASR(W)] due to GBC was
extracted separately for males and females for the
period 19922002 for 50 countries across the world.
The database contains cancer mortality statistics by
country extracted from the World Health Organiza-
tion (WHO) databank. The original data have been
converted and/or recorded to a common system and
the information on quality of data, such as presence of
histological ascertainment, extent of population cov-
erage, and percentage of death certificate only regis-
tration, is not available. Of the 115 WHO member
states that have some method of death registration,
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only 29 have an ‘‘ideal’’ civil registration system, while
countries such as China and India have only a
‘‘sample’’ registration system [12]. Data were thus
available from 32 countries in Europe (West Europe:
Belgium, France, Germany, Ireland, Luxembourg,
The Netherlands, Switzerland, and the United King-
dom; East Europe: Estonia, Latvia, Lithuania, Mol-
dova, Poland, and Romania; North Europe: Denmark,
Finland, Iceland, Norway, and Sweden; South Europe:
Albania, Croatia, Greece, Italy, Macedonia, Malta,
Portugal, Slovenia, and Spain; Central Europe: Austria,
Czechoslovakia, Hungary, and Slovakia), 10 countries
in Asia (South East Asia: Hong Kong, Philippines,
Singapore, and Thailand; North East Asia: Japan,
Korea; Middle East: Georgia, Israel, Kuwait, and
Kyrgyzstan), and 8 countries across the Americas
(North America: Canada and the United States of
America; South America: Colombia, Costa Rica,
Ecuador, Mexico, Uruguay, and Venezuela). Log-
linear regression was used to analyse trends for the
period 19922002. Correlation coefficients were cal-
culated, with a positive value indicating an increasing
trend and a negative value a falling trend; pB0.05 was
considered significant.
Results
Europe
The ASR(W) due to GBC in the period 19922002
for both males and females has been static across most
countries in Europe. Hungary and Czechoslovakia in
Central Europe were exceptions, with mortality rates
highest in 1992 for both sexes: males (6.5 and 6.4,
respectively) and females (12 and 9.2, respectively),
declining to 4.6 and 4.5, respectively, in the case of
males, and 4.8 and 4.6, respectively, in the case of
females in 2002. The mortality rates were high in
Germany, Sweden, and Slovenia in 1992 [male range
(3.44.8), female range (5.36.8)] with subsequent
decrease in 2002 [male range (1.72.0), female range
(2.23.1)]. The decreasing trends (both sexes) were
found to be highly significant in Hungary, Germany,
and Sweden (pB0.001), while the decline in trend
was more significant in females than in males in
Czechoslovakia and Austria (females pB0.01; males
pB0.05). Declining trends in mortality for both sexes
(pB0.01) were also seen in the UK, The Netherlands,
and France, while in Denmark, Slovenia, and Spain
the downward trend was more significant in women
(pB0.001) compared to men (pB0.05). Decreasing
trends solely in women were noted in Finland, Italy,
Portugal (pB0.01), and in Georgia, Luxembourg,
and Belgium (pB0.05).
Iceland was the only country in Europe where a
significant increase in mortality trends (pB0.05) was
seen in the case of males (0.75 in 1992 to 2 in 2002)
due to GBC, while mortality trends in the case of
women did not attain significance.
Asia
The decline in ASR(W) in both males and females
due to GBC in the period 19922002 was seen in
Japan, Hong Kong, and Israel. Mortality trends
decreased in Japan and Hong Kong (pB0.01), while
in Israel the downward trend was more significant in
women (pB0.01) compared to men (pB0.05).Korea
was the only country in Asia to register increasing
mortality rates for both males (6 in 1995 to 8 in 2001)
and females (3.2 in 1995 to 5 in 2001), and this
upward trend was more significant in women (pB
0.01) than in men (pB0.05) (data unavailable prior
to 1995).
North America
The decreasing mortality rates due to GBC in Canada
and the USA in the period 1992–2002 were replicated
in both sexes, while the mortality trends were more
significant in Canadian women (pB0.001) than in
Canadian men (pB0.01).
South America
The analysis of age standardized mortality rates in the
period 19922002 was limited to Columbia, Costa
Rica, and Ecuador, with no data available after 1997.
Mortality rates remained static for women across
these countries, with a decrease in male mortality in
Ecuador and Columbia, barring Costa Rica, where
male mortality increased from 1.6 in 1992 to 2.2 in
1997, this upward trend being significant (pB0.05).
Discussion
Our analysis suggests that, in the Western world,
mortality due to GBC fell in the last decade of the
second millennium. However, this is in stark contrast
to the increase seen in Korea, Costa Rica, and
Iceland. The first possibility is the variation in quality
of data available in international registries, along with
the absence of incidence data, population size, and
demographics [13,14]. In addition, the extent of
histological verification is not available, nor is infor-
mation on diagnostic and treatment modalities used
for the tumors of the biliary tract. Few data were
available for the South American and Asian countries,
where the incidence of GBC is known to be high. We
have assumed the effects in all countries to be
equivalent regardless of population size and this can
be seen in Table I, as there is variation in the total
number of deaths for each country. However, the fact
that we used ASR(W), a standard comparative tool,
can account for some of the variation. Secondly, the
observed variations could reflect a consolidation of
the diagnostic modalities used [15,16]. The use of
high resolution CT scans/ERCP/MRCP/EUS/laparo-
scopy is now the norm in the West, leading to
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Table I. Significant trends in the mortality of gallbladder cancer, 19922002.
Males Females
Region Country Deaths (range) Coefficient 95% CI p-value Deaths (range) Coefficient 95% CI p-value
Northern Europe Denmark 3653 0.034 (0.076, 0.008) 0.1 59109 0.077 (0.091, 0.062) B0.001
Finland 4472 NS 119174 0.052 (0.076, 0.028) 0.001
Iceland 1 to 3 0.095 (0.005, 0.185) 0.04 010 NS
Norway 4054 NS 5591 0.031 (0.069, 0.006) 0.09
Sweden 181296 0.064 (0.086, 0.043) B0.001 343681 0.087 (0.115, 0.059) B0.001
Southern Europe Albania 1 to 10 NS 1 to 6 NS
Croatia 5177 NS 105162 NS
Greece 79157 NS 119190 NS
Italy 13861645 NS 28763086 0.017 (0.024, 0.009) 0.001
Macedonia 9 to 21 NS 1736 NS
Malta 05 NS 06 0.112 (0.245, 0.022) 0.09
Portugal 118180 NS 161277 0.054 (0.084, 0.023) 0.003
Slovenia 3356 0.05 (0.087, 0.013) 0.01 60138 0.108 (0.132, 0.084) B0.001
Spain 437662 0.042 (0.074, 0.009) 0.02 8951523 0.078 (0.108, 0.047) B0.001
Western Europe Belgium 97198 0.116 (0.244, 0.012) 0.07 172346 0.12 (0.240, 0.004) 0.05
France 519850 0.064 (0.093, 0.035) 0.001 8311690 0.082 (0.118, 0.046) 0.001
Germany 12822070 0.075 (0.095, 0.056) B0.001 28256172 0.109 (0.139, 0.079) B0.001
Ireland 1739 NS 3877 NS
Luxembourg 06 NS 2 to 9 0.133 (0.263, 0.003) 0.05
Netherlands 102215 0.087 (0.130, 0.044) 0.001 184490 0.123 (0.154, 0.091) B0.001
Switzerland 7185 NS 174187 0.043 (0.021, 0.107) 0.07
UK 198458 0.078 (0.103, 0.054) B0.001 392889 0.067 (0.100, 0.034) 0.001
Central Europe Austria 125231 0.042 (0.077, 0.008 0.02 232646 0.065 (0.104, 0.027) 0.004
Czech 268436 0.043 (0.071, 0.016) 0.01 5491004 0.065 (0.093, 0.037) 0.001
Hungary 243490 0.075 (0.010, 0.046) B0.001 5771436 0.116 (0.150, 0.081) B0.001
Slovakia 78102 191249
Middle East Asia Israel 059 0.16 (0.256, 0.052) 0.01 0118 0.139 (0.214, 0.064) 0.003
Kuwait 05 2 to 5 0.071 (0.155, 0.013) 0.09
North Asia Georgia 2 to 7 NS 5 to 17 0.384 (0.667, 0.109) 0.03
Russia NA NS NA
Kyrgyzstan 8 to 12 NS 15 to 26
North East Asia Japan 61897885 0.043 (0.060, 0.026) B0.001 755711616 0.078 (0.108, 0.048) B0.001
Korea 9831599 0.025 (0.002, 0.049) 0.04 7681413 0.049 (0.025, 0.072) 0.002
South East Asia Hong Kong 5186 0.074 (0.101, 0.046) B0.001 7096 0.047 (0.078, 0.015) 0.008
Philippines 4262 NS 4163 NS
Singapore 1738 NS 2158 NS
Thailand NA 0.114 (0.260, 0.032) 0.1 NA NS
North America Canada 188326 0.068 (0.099, 0.038) 0.001 294562 0.09 (0.118, 0.063) B0.001
USA 12882008 0.072 (0.094, 0.051) B0.001 40772120 0.09 (0.012. 0.060) B0.001
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improved clinical diagnosis of gallstone disease (a
known risk factor) as well as better separation of
GBCs from bile duct cancers. The incorporation of
these modalities has also led to: 1) improved diagnosis
and standardization of treatment of gallstone disease
using laparoscopic cholecystectomy, which probably
reduces the risk of development of GBC, contributing
to the decreasing trend. This hypothesis will need to
be tested in population-based studies; 2) a corre-
sponding increase in the diagnosis of hilar cholangio-
carcinomas, a common differential diagnosis of GBCs
causing biliary obstruction: these are classified as
intrahepatic cholangiocarcinomas by the International
Classification of Diseases-10 (ICD-10). This increase
has been reported recently [15,17]; and 3) the re-
classification of hepatobiliary tumors that would
previously have been described as cholangiocarcino-
mas, hepatocellular carcinomas, or unclassified
[15,17].
This revision of ICD-10 in 1992 may have further
contributed to the declining trend because, for the
first time, GBC was classified separately from other
cancers affecting the biliary tract [18].
Lastly, we have to consider that the changes we
have observed are real. However, further in-depth
analysis is required if definitive trends are to be
ascertained, and for which larger datasets would be
required over longer periods of time (more than 20
years) along with incidence data and demographics.
These data are currently unavailable for the majority
of countries.
Randi et al., in reviewing the incidence of GBC
worldwide, found that the highest incidence (data
post mid-1990s) was in women from Delhi, India
(21.5/100,000), South Karachi, Pakistan (13.8/
100,000), and Quito, Ecuador (12.9/100,000) [11].
Among men, the highest incidence was in Busan,
Korea (8/100,000), and Delhi, India (7.5/100,000).
High incidences of GBC (women: 811/100,000,
men: 38/100,000) in cancer registries were found
in Korea, Japan, countries of eastern Europe (Slova-
kia, Poland, Czech Republic, and Yugoslavia), while
low incidence rates were observed in most registries
across northern Europe barring Sweden and North
America. The female/male ratio also varied, with the
highest ratio in Pakistan, Columbia, and Spain. The
sex ratio in the vast majority of countries was between
2 and 3, while the incidence in males and females was
virtually equal in Korea, Japan, and some parts of
China. Unfortunately, data for these countries were
sparse in our study.
This variation can also be seen among ethnic
groups, where Hispanic white women in California
and New Mexico showed a 3 to 5-fold higher
incidence (85.4/100,000) than non-Hispanic women
in the same areas. American Indians too exhibited
a high incidence of GBC. This ethnic variation is
less prominent among men, barring American In-
dians. Various inferences can be drawn from theseT
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differences, especially with the worldwide distribution
of gallstones, which has a strong positive correlation
with the incidence of GBC [9,10]. A high prevalence
of gallstones was reported in the regions of South
America and parts of Eastern and Central Europe
[11]. Thus, the prevention of gallstones may impor-
tant in decreasing the incidence of GBC, especially in
high-risk areas.
Through this preliminary analysis, we have at-
tempted to explain the variations in GBC mortality
in different parts of the world. Insights that may be
gained from this study include the changed use of
various diagnostic modalities and that may explain the
differences seen. The epidemiologies of gallbladder
and related cancers deserve a more in-depth study
when more data become available.
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